Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.09
WOOF's Cash-to-Debt is ranked lower than
75% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.37 vs. WOOF: 0.09 )
Ranked among companies with meaningful Cash-to-Debt only.
WOOF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.16 Max: No Debt
Current: 0.09
Equity-to-Asset 0.45
WOOF's Equity-to-Asset is ranked lower than
57% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. WOOF: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
WOOF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.49 Max: 0.68
Current: 0.45
0.1
0.68
Debt-to-Equity 0.86
WOOF's Debt-to-Equity is ranked lower than
63% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.63 vs. WOOF: 0.86 )
Ranked among companies with meaningful Debt-to-Equity only.
WOOF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03  Med: 0.71 Max: 9.67
Current: 0.86
0.03
9.67
Debt-to-EBITDA 2.62
WOOF's Debt-to-EBITDA is ranked higher than
53% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 2.82 vs. WOOF: 2.62 )
Ranked among companies with meaningful Debt-to-EBITDA only.
WOOF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.07  Med: 2.01 Max: 3.59
Current: 2.62
0.07
3.59
Interest Coverage 10.52
WOOF's Interest Coverage is ranked higher than
57% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 7.55 vs. WOOF: 10.52 )
Ranked among companies with meaningful Interest Coverage only.
WOOF' s Interest Coverage Range Over the Past 10 Years
Min: 5.46  Med: 11.47 Max: 15.55
Current: 10.52
5.46
15.55
Piotroski F-Score: 3
Altman Z-Score: 4.13
Beneish M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.89
WOOF's Operating Margin % is ranked higher than
76% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. WOOF: 14.89 )
Ranked among companies with meaningful Operating Margin % only.
WOOF' s Operating Margin % Range Over the Past 10 Years
Min: 5.47  Med: 15.18 Max: 20.17
Current: 14.89
5.47
20.17
Net Margin % 8.00
WOOF's Net Margin % is ranked higher than
68% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 4.16 vs. WOOF: 8.00 )
Ranked among companies with meaningful Net Margin % only.
WOOF' s Net Margin % Range Over the Past 10 Years
Min: 2.68  Med: 8.15 Max: 10.47
Current: 8
2.68
10.47
ROE % 18.48
WOOF's ROE % is ranked higher than
79% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 9.23 vs. WOOF: 18.48 )
Ranked among companies with meaningful ROE % only.
WOOF' s ROE % Range Over the Past 10 Years
Min: 3.98  Med: 13.59 Max: 24.23
Current: 18.48
3.98
24.23
ROA % 8.19
WOOF's ROA % is ranked higher than
77% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. WOOF: 8.19 )
Ranked among companies with meaningful ROA % only.
WOOF' s ROA % Range Over the Past 10 Years
Min: 2.23  Med: 6.81 Max: 10.72
Current: 8.19
2.23
10.72
ROC (Joel Greenblatt) % 84.33
WOOF's ROC (Joel Greenblatt) % is ranked higher than
86% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. WOOF: 84.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
WOOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 23.39  Med: 64.63 Max: 116.35
Current: 84.33
23.39
116.35
3-Year Revenue Growth Rate 15.30
WOOF's 3-Year Revenue Growth Rate is ranked higher than
75% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. WOOF: 15.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
WOOF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.6 Max: 134.1
Current: 15.3
0
134.1
3-Year EBITDA Growth Rate 18.00
WOOF's 3-Year EBITDA Growth Rate is ranked higher than
75% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. WOOF: 18.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
WOOF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -1.4 Max: 225.3
Current: 18
0
225.3
3-Year EPS without NRI Growth Rate 18.70
WOOF's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 163 Companies
in the Global Medical Care industry.

( Industry Median: 7.00 vs. WOOF: 18.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
WOOF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -11.1 Max: 100
Current: 18.7
0
100
GuruFocus has detected 4 Warning Signs with VCA Inc WOOF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» WOOF's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

WOOF Guru Trades in Q3 2016

Paul Tudor Jones 3,900 sh (New)
Ken Fisher 2,921 sh (New)
Steven Cohen 78,700 sh (+487.31%)
Pioneer Investments 111,151 sh (+4.43%)
Larry Robbins Sold Out
Columbia Wanger 195,940 sh (-2.41%)
Third Avenue Management 80,794 sh (-13.63%)
Jim Simons 615,000 sh (-27.94%)
» More
Q4 2016

WOOF Guru Trades in Q4 2016

Andreas Halvorsen 545,862 sh (New)
Robert Olstein 122,150 sh (New)
Mario Gabelli 9,000 sh (New)
Columbia Wanger 893,802 sh (+356.16%)
Steven Cohen 307,200 sh (+290.34%)
Ken Fisher 2,921 sh (unchged)
Paul Tudor Jones Sold Out
Third Avenue Management 80,458 sh (-0.42%)
Pioneer Investments 71,538 sh (-35.64%)
Jim Simons 101,400 sh (-83.51%)
» More
Q1 2017

WOOF Guru Trades in Q1 2017

Paul Tudor Jones 370,000 sh (New)
Mario Gabelli 316,700 sh (+3418.89%)
Jim Simons 242,000 sh (+138.66%)
Third Avenue Management 80,458 sh (unchged)
Ken Fisher 2,921 sh (unchged)
Columbia Wanger Sold Out
Pioneer Investments Sold Out
Robert Olstein Sold Out
Steven Cohen Sold Out
Andreas Halvorsen Sold Out
» More
Q2 2017

WOOF Guru Trades in Q2 2017

Jim Simons 617,700 sh (+155.25%)
Ken Fisher 3,171 sh (+8.56%)
Mario Gabelli 317,000 sh (+0.09%)
Paul Tudor Jones 365,514 sh (-1.21%)
Third Avenue Management 57,158 sh (-28.96%)
» More
» Details

Insider Trades

Latest Guru Trades with WOOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2017-06-30 Add 0.09%$91.43 - $92.65 $ 92.981%317,000
Third Avenue Management 2017-06-30 Reduce -28.96%0.1%$91.43 - $92.65 $ 92.981%57,158
Ken Fisher 2017-06-30 Add 8.56%$91.43 - $92.65 $ 92.981%3,171
Mario Gabelli 2017-03-31 Add 3418.89%0.17%$70.29 - $91.58 $ 92.984%316,700
Robert Olstein 2017-03-31 Sold Out 1.08%$70.29 - $91.58 $ 92.984%0
Robert Olstein 2016-12-31 New Buy1.08%$59.61 - $71.16 $ 92.9842%122,150
Third Avenue Management 2016-12-31 Reduce -0.42%$59.61 - $71.16 $ 92.9842%80,458
Mario Gabelli 2016-12-31 New Buy$59.61 - $71.16 $ 92.9842%9,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 541940    SIC: 742
Compare:LSE:NMC, ASX:SHL, LSE:MDC, HAM:CLS1, SZSE:300015, BKK:BDMS, NYSE:EVHC, ASX:RHC, BKK:BH, NYSE:UHS, NYSE:HLS, NAS:ACHC, NYSE:MD, NYSE:DVA, XKLS:5225, NYSE:CHE, XSGO:BANMEDICA, NYSE:SEM, JSE:NTC, ASX:HSO » details
Traded in other countries:VCA.Germany,
Headquarter Location:USA
VCA Inc operates in the healthcare sector. Its primary activity involves veterinary services and diagnostic testing.

Founded in 1986, VCA is the largest operator of freestanding, full-service animal hospitals and veterinary diagnostic labs in the United States. With nearly 800 pet hospitals, 61 reference labs, and 3,000 vets, the firm handled 11.8 million patient visits in 2016. It traded publicly from 1991 to 2000. After the company ran up a huge debt load to fund a buying binge in the late 1990s, a private investment group purchased and recapitalized the firm. VCA went public again in 2001.

Top Ranked Articles about VCA Inc

Mars, Incorporated Completes Acquisition of VCA Inc.
Camp Bow Wow Inspires Consumers to #GiveAFetch through New Campaign
Mars, Incorporated Receives U.S. Federal Trade Commission Clearance for Acquisition of VCA
Camp Bow Wow Designs New Colorado Headquarters to Amplify Its Dog-Friendly Policy Amid Growth
Paul Tudor Jones’ Top 4 Health Care Buys Guru invested in multiple health care stocks in 1st quarter
Paul Tudor Jones (Trades, Portfolio)’ Tudor Investment Corp. gained 325 new holdings during the first quarter. Among his purchases were multiple health care stocks including VCA Inc. (NASDAQ:WOOF), DaVita Inc. (NYSE:DVA), Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) and Edwards Lifesciences Corp. (NYSE:EW). Read more...
Camp Bow Wow Displays One of its Strongest Years of Growth at Close of 2016 and Propels its Successes into 2017
Columbia Wanger Buys LCI Industries, Nasdaq Largest buys by the firm in the 4th quarter
Columbia Wanger (Trades, Portfolio) manages a portfolio composed of 197 stocks with a total value of $7.123 billion. During the fourth quarter the guru bought shares in the following stocks: Read more...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against VCA Inc.

WILMINGTON, Del., March 07, 2017 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the Central District of California on behalf of holders of VCA Inc. (“VCA”) (NASDAQ:WOOF) common stock in connection with the proposed acquisition of VCA by MMI Holdings, Inc., Venice Merger Sub Inc., and Mars, Incorporated (collectively, “Mars”) announced on January 9, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against VCA, its Board of Directors (the “Board”), and Mars, is captioned Hight v. VCA Inc., Case No. 17-cv-00289 (C.D. Cal.). If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at [email protected]; or at: http://rigrodskylong.com/investigations/vca-inc-woof/. On January 7, 2017, VCA entered into an agreement and plan of merger (the “Merger Agreement”) with Mars.  Pursuant to the Merger Agreement, VCA shareholders will receive $93.00 per share in cash in a transaction valued at approximately $9.1 billion (the “Proposed Transaction”). Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a proxy statement (the “Proxy Statement”) filed with the United States Securities and Exchange Commission on February 3, 2017.  The Proxy Statement, which recommends that VCA stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to VCA’s financial projections and the opinions and analyses of VCA’s financial advisor.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of VCA common stock.  If you wish to serve as lead plaintiff, you must move the Court no later than May 8, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States. Attorney advertising.  Prior results do not guarantee a similar outcome.
CONTACT:

Rigrodsky & Long, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242
(302) 295-5310
Fax: (302) 654-7530
[email protected]
http://www.rigrodskylong.com

Read more...
Stocks Steven Cohen Continues to Buy The investor purchased shares of these companies during the last 2 quarters
Steven Cohen (Trades, Portfolio), a billionaire hedge fund investor, is the founder of SAC Capital Advisors, a Stamford, Connecticut-based hedge fund that he continues to manage. He manages a portfolio composed of 668 stocks with a total value of $14.303 billion. In both the fourth and third quarters of 2016 the guru bought shares in the following stocks: Read more...
Health Care Companies Showing Good Defensive Potential Deep analysis of historical financial trends for health care companies
Among U.S. companies, health care companies offer good defensive-investing opportunities. Such companies, including Johnson & Johnson (NYSE:JNJ), Biogen Inc. (NASDAQ:BIIB) and VCA Inc. (NASDAQ:WOOF), generally had strong financial strength and gross margins. Read more...

Ratios

vs
industry
vs
history
PE Ratio 35.09
WOOF's PE Ratio is ranked lower than
66% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. WOOF: 35.09 )
Ranked among companies with meaningful PE Ratio only.
WOOF' s PE Ratio Range Over the Past 10 Years
Min: 10.31  Med: 21.61 Max: 56.8
Current: 35.09
10.31
56.8
Forward PE Ratio 26.25
WOOF's Forward PE Ratio is ranked lower than
78% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 19.88 vs. WOOF: 26.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 35.09
WOOF's PE Ratio without NRI is ranked lower than
66% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. WOOF: 35.09 )
Ranked among companies with meaningful PE Ratio without NRI only.
WOOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.31  Med: 21.61 Max: 56.8
Current: 35.09
10.31
56.8
Price-to-Owner-Earnings 26.02
WOOF's Price-to-Owner-Earnings is ranked higher than
52% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 26.22 vs. WOOF: 26.02 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WOOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.68  Med: 20.81 Max: 67.8
Current: 26.02
9.68
67.8
PB Ratio 4.70
WOOF's PB Ratio is ranked lower than
76% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 2.62 vs. WOOF: 4.70 )
Ranked among companies with meaningful PB Ratio only.
WOOF' s PB Ratio Range Over the Past 10 Years
Min: 1.23  Med: 2.6 Max: 7.52
Current: 4.7
1.23
7.52
PS Ratio 2.80
WOOF's PS Ratio is ranked lower than
68% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. WOOF: 2.80 )
Ranked among companies with meaningful PS Ratio only.
WOOF' s PS Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.74 Max: 3.42
Current: 2.8
0.94
3.42
Price-to-Free-Cash-Flow 25.80
WOOF's Price-to-Free-Cash-Flow is ranked lower than
60% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 22.48 vs. WOOF: 25.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WOOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.46  Med: 18.35 Max: 37.05
Current: 25.8
10.46
37.05
Price-to-Operating-Cash-Flow 18.41
WOOF's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 14.62 vs. WOOF: 18.41 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WOOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.26  Med: 12.52 Max: 26.1
Current: 18.41
7.26
26.1
EV-to-EBIT 21.86
WOOF's EV-to-EBIT is ranked lower than
52% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 20.85 vs. WOOF: 21.86 )
Ranked among companies with meaningful EV-to-EBIT only.
WOOF' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.3  Med: 13.7 Max: 29.5
Current: 21.86
7.3
29.5
EV-to-EBITDA 16.99
WOOF's EV-to-EBITDA is ranked lower than
57% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 15.17 vs. WOOF: 16.99 )
Ranked among companies with meaningful EV-to-EBITDA only.
WOOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.5  Med: 11.2 Max: 17.2
Current: 16.99
6.5
17.2
EV-to-Revenue 3.27
WOOF's EV-to-Revenue is ranked lower than
68% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. WOOF: 3.27 )
Ranked among companies with meaningful EV-to-Revenue only.
WOOF' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 2 Max: 3.8
Current: 3.27
1.3
3.8
PEG Ratio 1.65
WOOF's PEG Ratio is ranked higher than
72% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 3.00 vs. WOOF: 1.65 )
Ranked among companies with meaningful PEG Ratio only.
WOOF' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.42 Max: 76.52
Current: 1.65
0.5
76.52
Shiller PE Ratio 53.58
WOOF's Shiller PE Ratio is ranked lower than
75% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 27.79 vs. WOOF: 53.58 )
Ranked among companies with meaningful Shiller PE Ratio only.
WOOF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.95  Med: 30.03 Max: 77.5
Current: 53.58
14.95
77.5
Current Ratio 1.01
WOOF's Current Ratio is ranked lower than
67% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.41 vs. WOOF: 1.01 )
Ranked among companies with meaningful Current Ratio only.
WOOF' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.53 Max: 6.15
Current: 1.01
0.52
6.15
Quick Ratio 0.83
WOOF's Quick Ratio is ranked lower than
70% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. WOOF: 0.83 )
Ranked among companies with meaningful Quick Ratio only.
WOOF' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.34 Max: 5.95
Current: 0.83
0.47
5.95
Days Inventory 8.27
WOOF's Days Inventory is ranked higher than
73% of the 199 Companies
in the Global Medical Care industry.

( Industry Median: 16.86 vs. WOOF: 8.27 )
Ranked among companies with meaningful Days Inventory only.
WOOF' s Days Inventory Range Over the Past 10 Years
Min: 8.27  Med: 12.37 Max: 14.23
Current: 8.27
8.27
14.23
Days Sales Outstanding 11.58
WOOF's Days Sales Outstanding is ranked higher than
87% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.26 vs. WOOF: 11.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
WOOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.51  Med: 12.72 Max: 14.32
Current: 11.58
11.51
14.32
Days Payable 9.99
WOOF's Days Payable is ranked lower than
87% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: 51.14 vs. WOOF: 9.99 )
Ranked among companies with meaningful Days Payable only.
WOOF' s Days Payable Range Over the Past 10 Years
Min: 9.68  Med: 11.29 Max: 13.01
Current: 9.99
9.68
13.01

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 2.80
WOOF's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. WOOF: 2.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WOOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4  Med: 3 Max: 0
Current: 2.8
-4
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.98
WOOF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
51% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 1.98 vs. WOOF: 1.98 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WOOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.63  Med: 1.61 Max: 113.29
Current: 1.98
0.63
113.29
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.28
WOOF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
92% of the 36 Companies
in the Global Medical Care industry.

( Industry Median: 1.59 vs. WOOF: 3.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
WOOF' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 1.49  Med: 2.02 Max: 3.28
Current: 3.28
1.49
3.28
Price-to-Median-PS-Value 1.61
WOOF's Price-to-Median-PS-Value is ranked lower than
79% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. WOOF: 1.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WOOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.15 Max: 2.76
Current: 1.61
0.55
2.76
Price-to-Peter-Lynch-Fair-Value 1.40
WOOF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
65% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. WOOF: 1.40 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WOOF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.66  Med: 1.26 Max: 5.98
Current: 1.4
0.66
5.98
Earnings Yield (Greenblatt) % 4.57
WOOF's Earnings Yield (Greenblatt) % is ranked higher than
60% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. WOOF: 4.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WOOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 7.3 Max: 13.8
Current: 4.57
3.4
13.8
Forward Rate of Return (Yacktman) % 29.13
WOOF's Forward Rate of Return (Yacktman) % is ranked higher than
88% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 8.93 vs. WOOF: 29.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WOOF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -3.4  Med: 17.3 Max: 32.8
Current: 29.13
-3.4
32.8

More Statistics

Revenue (TTM) (Mil) $2,721.32
EPS (TTM) $ 2.65
Short Percentage of Float1.63%
52-Week Range $59.51 - 93.00
Shares Outstanding (Mil)81.27

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 2,758 3,047
EPS ($) 3.15 3.54
EPS without NRI ($) 3.15 3.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.46%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}